{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:43:44Z","timestamp":1791225824268,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Instituto de Qu\u00edmica, UNAM"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.drudis.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T17:32:16Z","timestamp":1500744736000},"page":"1719-1729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?"],"prefix":"10.1016","volume":"22","author":[{"given":"Abraham","family":"Madariaga-Maz\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Marmolejo-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Toll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Houghten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Martinez-Mayorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2017.07.002_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pep.2017.03.002","article-title":"Method for rapid optimization of recombinant GPCR protein expression and stability using virus-like particles","volume":"133","author":"Ho","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.drudis.2017.07.002_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/pr.57.2.2","article-title":"Multiple signaling states of G-protein-coupled receptors","volume":"57","author":"Perez","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2017.07.002_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2017.07.002_bib0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-1708-2_7","article-title":"In vivo techniques to investigate the internalization profile of opioid receptors","volume":"1230","author":"Pradhan","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejphar.2015.05.012","article-title":"Opioid receptors: structural and mechanistic insights into pharmacology and signaling","volume":"763","author":"Shang","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-1708-2_1","article-title":"Overview of genetic analysis of human opioid receptors","volume":"1230","author":"Spampinato","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","article-title":"The delta opioid receptor: an evolving target for the treatment of brain disorders","volume":"32","author":"Pradhan","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0040","series-title":"Pain Management\u2014Current Issues and Opinions","first-page":"43","article-title":"Molecular aspects of opioid receptors and opioid receptor painkillers","author":"Yongye","year":"2012"},{"key":"10.1016\/j.drudis.2017.07.002_bib0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2008.07.033","article-title":"Opioid receptors: from binding sites to visible molecules in vivo","volume":"56","author":"Kieffer","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.07.002_bib0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejmech.2016.09.003","article-title":"Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists","volume":"126","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0055","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.bmcl.2015.07.064","article-title":"Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives","volume":"25","author":"Deekonda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2017.07.002_bib0060","series-title":"Pain Management\u2014Current Issues and Opinions","first-page":"288","article-title":"Opioid analgesics","author":"Maree","year":"2012"},{"key":"10.1016\/j.drudis.2017.07.002_bib0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tips.2016.01.001","article-title":"New technologies for elucidating opioid receptor function","volume":"37","author":"Bruchas","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0070","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/0929867323666160427123005","article-title":"Cyclic opioid peptides","volume":"23","author":"Remesic","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/co300110t","article-title":"Fluorescent Mu selective opioid ligands from a mixture based cyclic peptide library","volume":"14","author":"Li","year":"2012","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bph.12599","article-title":"Positive allosteric modulators of the \u03bc-opioid receptor: a novel approach for future pain medications","volume":"172","author":"Burford","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2008.11.004","article-title":"Role of delta opioid efficacy as a determinant of mu\/delta opioid interactions in rhesus monkeys","volume":"602","author":"Negus","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0090","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.109.157446","article-title":"Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor\/\u03bc-opioid receptor ligands: implications for therapeutic Applications","volume":"331","author":"Toll","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0095","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1021\/acs.jmedchem.5b01270","article-title":"Further optimization and evaluation of bioavailable, mixed-efficacy \u03bc-opioid receptor (MOR) agonists\/\u03bc-opioid receptor (DOR) antagonists: balancing MOR and DOR affinities","volume":"58","author":"Harland","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40265-017-0756-7","article-title":"Eluxadoline: a review in diarrhoea-predominant irritable bowel syndrome","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2017.07.002_bib0105","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the\u039c-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2017.07.002_bib0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","article-title":"Structure-function of the G protein-coupled receptor superfamily","volume":"53","author":"Katritch","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tips.2012.10.002","article-title":"Grand opening of structure-guided design for novel opioids","volume":"34","author":"Filizola","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-1708-2_2","article-title":"Computational structural biology of opioid receptors","volume":"1230","author":"Provasi","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/acschemneuro.5b00245","article-title":"17-Cyclopropylmethyl-3, 14\u03b2-dihydroxy-4, 5\u03b1-epoxy-6\u03b2-(4\u2032-pyridylcarboxamido)morphinan (NAP) modulating the mu opioid receptor in a biased fashion","volume":"7","author":"Zhang","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2015.09.024","article-title":"Biasing the odds: approaches to capturing, understanding and exploiting functional selectivity in GPCRs","volume":"92","author":"H\u00e9bert","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2017.07.002_bib0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2017.07.002_bib0145","first-page":"1","article-title":"Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery?","volume":"99","author":"Anderson","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0150","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a G protein biased m opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0155","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1021\/acs.jmedchem.6b01194","article-title":"Design and discovery of functionally selective serotonin 2C (5-HT2C) receptor agonists","volume":"59","author":"Cheng","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0160","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1074\/jbc.M114.596098","article-title":"Biased signaling at chemokine receptors","volume":"290","author":"Corbisier","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/mol.116.105940","article-title":"A pluridimensional view of biased agonism","volume":"90","author":"Costa-Neto","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4062\/biomolther.2016.165","article-title":"Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology","volume":"25","author":"Bologna","year":"2017","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0180","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1074\/jbc.M508074200","article-title":"A \u03b2-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors","volume":"281","author":"Marion","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/science.271.5247.363","article-title":"Role of beta-arrestin in mediating agonist-promoted g protein-coupled receptor internalization","volume":"5247","author":"Ferguson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.drudis.2017.07.002_bib0190","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking \u03b2-arrestin 2","volume":"5449","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.drudis.2017.07.002_bib0195","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"\u039c-Opioid receptor desensitization by \u03b2-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Caron","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2017.07.002_bib0200","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin-2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0205","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1124\/mol.115.098848","article-title":"Biased agonism of endogenous opioid peptides at the mu-opioid receptor","volume":"88","author":"Thompson","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.112.078659","article-title":"Endomorphin-2: a biased agonist at the \u03bc-opioid receptor","volume":"82","author":"Rivero","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2015.12.024","article-title":"Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine","volume":"105","author":"Zadina","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.07.002_bib0220","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1021\/jm048963m","article-title":"Neoclerodane diterpenes as a novel scaffold for m opioid receptor ligands","volume":"48","author":"Harding","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2011.10.026","article-title":"Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology","volume":"121","author":"Lamb","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drudis.2017.07.002_bib0230","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/mol.106.028258","article-title":"An opioid agonist that does not induce \u039c-opioid receptor-arrestin interactions or receptor internalization","volume":"71","author":"Groer","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0235","doi-asserted-by":"crossref","first-page":"e93688","DOI":"10.1371\/journal.pone.0093688","article-title":"Activation of mu opioid receptors sensitizes Transient Receptor Potential Vanilloid Type 1 (TRPV1) via \u03b2-arrestin-2-mediated cross-talk","volume":"9","author":"Rowan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2017.07.002_bib0240","first-page":"1","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"130","author":"Altarifi","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0245","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/acs.biochem.6b00948","article-title":"How oliceridine (trv-130) binds and stabilizes a \u03b2-opioid receptor conformational state that selectively triggers G protein signaling pathways","volume":"55","author":"Schneider","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2017.07.002_bib0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2017.07.002_bib0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0306-3623(98)00265-1","article-title":"Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa","volume":"33","author":"Yamamoto","year":"1999","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0260","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.3390\/ijms130911427","article-title":"Antinociceptive action of isolated mitragynine from mitragyna speciosa through activation of opioid receptor system","volume":"13","author":"Shamima","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0265","first-page":"792","article-title":"Pharmacology of Kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects","volume":"112","author":"Prozialeck","year":"2012","journal-title":"J. Am. Osteopath. Assoc."},{"key":"10.1016\/j.drudis.2017.07.002_bib0270","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2017.07.002_bib0275","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0280","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, synthesis, and biological evaluation of 6\u03b1- and 6\u03b2-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0285","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejphar.2013.01.060","article-title":"Ligand interaction, binding site and G protein activation of the mu opioid receptor","volume":"702","author":"Cui","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.drudis.2017.07.002_bib0295","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10822-017-0016-7","article-title":"Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist","volume":"31","author":"Marmolejo-Valencia","year":"2017","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.drudis.2017.07.002_bib0300","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tibs.2014.03.002","article-title":"Allosteric sodium in class A GPCR signaling","volume":"39","author":"Katritch","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0305","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejphar.2013.01.060","article-title":"Ligand interaction, binding site and G protein activation of the mu opioid receptor","volume":"702","author":"Cui","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0310","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/jm400050y","article-title":"Opioid peptidomimetics: leads for the design of bioavailable mixed efficacyM opioid receptor (MOR) agonist\/\u03b4 opioid receptor (DOR) antagonist ligands","volume":"56","author":"Mosberg","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0315","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/med.10059","article-title":"Recent advances in selective opioid receptor agonists and antagonists","volume":"24","author":"Eguchi","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2017.07.002_bib0320","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1573409910666141031093504","article-title":"A structural feature of the non-peptide ligand interactions with mice mu-opioid receptors","volume":"10","author":"Noori","year":"2014","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.drudis.2017.07.002_bib0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4939-2914-6_20","article-title":"Interaction fingerprints and their applications to identify hot spots","volume":"1335","author":"Marmolejo","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnins.2017.00017","article-title":"A practical guide to approaching biased agonism at G protein coupled receptors","volume":"11","author":"Gundry","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0335","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2016.05.014","article-title":"Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor","volume":"113","author":"Thompson","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0340","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/bph.13441","article-title":"Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased m opioid receptor agonists","volume":"173","author":"Winpenny","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.10.011","article-title":"Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: a practical guide to assessing functional data","volume":"101","author":"Stott","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0350","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/mol.111.072801","article-title":"Quantifying ligand bias at seven-transmembrane receptors","volume":"80","author":"Rajagopal","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0355","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0024-3205(87)90621-7","article-title":"Multiple mechanisms of serotonergic signal transduction","volume":"41","author":"Roth","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0360","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0026-895X(25)10934-6","article-title":"Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists","volume":"35","author":"Kenakin","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0365","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1074\/jbc.273.5.3097","article-title":"D-Arg1, d-Phe5, d-Trp(7,9), Leu11 substance P acts as a biased agonist toward neuropeptide and chemokine receptors","volume":"273","author":"Jarpe","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0370","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/jpet.301.3.1166","article-title":"Functional selectivity of dopamine receptor agonists: I. Selective activation of postsynaptic dopamine D-2 receptors linked to adenylate cyclase","volume":"301","author":"Mottola","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.phrs.2016.01.031","article-title":"Recent updates on GPCR biased agonism","volume":"112","author":"Pupo","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2017.07.002_bib0380","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2174\/138955712800959134","article-title":"Biased agonism of the angiotensin II type 1 receptor","volume":"12","author":"Godin","year":"2012","journal-title":"Mini. Rev. Med. Chem."},{"key":"10.1016\/j.drudis.2017.07.002_bib0385","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCHEARTFAILURE.112.969220","article-title":"TRV120027, a Novel \u03b2-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure clinical perspective","volume":"5","author":"Boerrigter","year":"2012","journal-title":"Circ. Hear. Fail."},{"key":"10.1016\/j.drudis.2017.07.002_bib0390","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cvr\/cvv162","article-title":"Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model","volume":"107","author":"Tarigopula","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2017.07.002_bib0395","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mce.2016.11.027","article-title":"Angiotensin type 1A receptor regulates \u03b2-arrestin binding of the (2-adrenergic receptor via heterodimerization","volume":"442","author":"T\u00f3th","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0400","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1021\/acs.jcim.6b00367","article-title":"Molecular mechanism of biased ligand conformational changes in CC chemokine receptor 7","volume":"56","author":"Gaieb","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.drudis.2017.07.002_bib0405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2016.07.018","article-title":"Cardiac action of the first G protein biased small molecule apelin agonist","volume":"116","author":"Read","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0410","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lfs.2016.02.069","article-title":"Evidence for biased agonists and antagonists at the endothelin receptors","volume":"159","author":"Maguire","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2017.07.002_bib0415","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-016-0401-4","article-title":"\u03b2-arrestin1 at the cross-road of endothelin-1 signaling in cancer","volume":"35","author":"Rosan\u00f2","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2017.07.002_bib0420","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.116.103283","article-title":"Structure-activity analysis of biased agonism at the human adenosine A3 receptor","volume":"90","author":"Baltos","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcp.2015.11.013","article-title":"Quantification of adenosine A1 receptor biased agonism: Implications for drug discovery","volume":"99","author":"Baltos","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0430","doi-asserted-by":"crossref","first-page":"26633","DOI":"10.1038\/srep26633","article-title":"Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacoMRI study","volume":"6","author":"Becker","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2017.07.002_bib0435","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: Preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.drudis.2017.07.002_bib0440","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1042\/BJ20150358","article-title":"Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways","volume":"470","author":"Liu","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2017.07.002_bib0445","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1087057116644162","article-title":"Development of a multiplex assay for studying functional selectivity of human serotonin 5-HT2A receptors and identification of active compounds by high-throughput screening","volume":"21","author":"Iglesias","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.drudis.2017.07.002_bib0450","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acschemneuro.5b00020","article-title":"Identification of G protein-biased agonists that fail to recruit \u03b2-arrestin or promote internalization of the d1 dopamine receptor","volume":"6","author":"Conroy","year":"2015","journal-title":"ACS Chem. Neurosci"},{"key":"10.1016\/j.drudis.2017.07.002_bib0455","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2017.07.002_bib0460","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/mol.113.090563","article-title":"Discovery and characterization of a G protein-biased agonist that inhibits \u03b2-arrestin recruitment to the D2 dopamine receptor","volume":"86","author":"Free","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0465","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.drudis.2017.07.002_bib0470","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G-protein biased partial (opioid receptor agonist 6\u2032-GNTI blocks hippocampal paroxysmal discharges without inducing aversion","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2017.07.002_bib0475","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1073\/pnas.1521825113","article-title":"Collybolide is a novel biased agonist of e-opioid receptors with potent antipruritic activity","volume":"113","author":"Gupta","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2017.07.002_bib0480","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuropharm.2015.08.032","article-title":"Noribogaine is a G-protein biased kappa-opioid receptor agonist","volume":"99","author":"Maillet","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.07.002_bib0485","doi-asserted-by":"crossref","first-page":"E4107","DOI":"10.1073\/pnas.1606267113","article-title":"\u03b2-Arrestin-biased signaling through the \u03b22-adrenergic receptor promotes cardiomyocyte contraction","volume":"113","author":"Carr","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2017.07.002_bib0490","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1042\/BJ20131226","article-title":"Signal transduction mechanism of biased ligands at histamine H2 receptors","volume":"459","author":"Alonso","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2017.07.002_bib0495","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuropharm.2015.11.005","article-title":"Cherry-picked ligands at histamine receptor subtypes","volume":"106","author":"Sadek","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2017.07.002_bib0500","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1038\/ncomms9918","article-title":"Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2017.07.002_bib0505","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.jmedchem.6b01448","article-title":"Pyrimidinyl biphenylureas: identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB 1","volume":"60","author":"Khurana","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616304974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616304974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:33:24Z","timestamp":1761222804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644616304974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1359644616304974"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2017.07.002","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}